TCGA-91-8496-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.330
- COAGULATION+0.320
- BILE_ACID_METABOLISM+0.310
- PANCREAS_BETA_CELLS+0.290
- KRAS_SIGNALING_UP+0.260
- ADIPOGENESIS+0.250
- ALLOGRAFT_REJECTION+0.250
- OXIDATIVE_PHOSPHORYLATION+0.240
- PEROXISOME+0.240
- COMPLEMENT+0.230
Top 10 suppressed
- G2M_CHECKPOINT-0.650
- E2F_TARGETS-0.600
- MITOTIC_SPINDLE-0.590
- MYC_TARGETS_V2-0.560
- MYC_TARGETS_V1-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.460
- WNT_BETA_CATENIN_SIGNALING-0.420
- MTORC1_SIGNALING-0.390
- PI3K_AKT_MTOR_SIGNALING-0.320
- SPERMATOGENESIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-67-3770-01A-01R-0946-07 | — | cohortA1 | 0.859 |
| 2 | TCGA-91-A4BD-01A-11R-A24H-07 | — | cohortA1 | 0.858 |
| 3 | TCGA-BA-A6DB-01A-11R-A30B-07 | — | — | 0.854 |
| 4 | TCGA-67-3773-01A-01R-0946-07 | — | cohortA1 | 0.854 |
| 5 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.850 |
| 6 | C3N-00223 | — | cohortA1 | 0.847 |
| 7 | MBCProject_0217_T2_RNA | — | C | 0.841 |
| 8 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.840 |
| 9 | TCGA-50-6597-01A-11R-1858-07 | — | cohortA1 | 0.834 |
| 10 | TCGA-50-8460-01A-11R-2326-07 | — | cohortA1 | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |